Wells Fargo raised the firm’s price target on Zymeworks (ZYME) to $14 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks upgraded to Overweight on 2025 pipeline at JPMorgan
- Zymeworks upgraded to Overweight from Neutral at JPMorgan
- Zymeworks Advances Oncology and Expands Therapeutic Reach
- Zymeworks hosts R&D day highlighting continued clinical progress
- Zymeworks to Showcase Innovations at Investor Conferences